Nemesis Bioscience announces research collaboration with Shionogi
Nemesis Bioscience Ltd announced that it has reached an agreement on terms for a two-year research collaboration with Shionogi & Co Ltd.
Nemesis Bioscience wins Innovate UK SBRI funding award
Nemesis Bioscience has been successful in winning a £414,000 award granted by the UK’s innovation agency, Innovate UK, for its pioneering approach of reversing bacterial resistance to existing antibiotics, as well as protecting the effectiveness of new antibiotics.
Japanese pharma company joins £1.4m seed funding round for Nemesis Bioscience
Nemesis Bioscience today announced the completion of a seed funding round of £1.4M from a syndicate of new investors including Shionogi & Co Ltd, Coastal International Holdings and Wren Capital in addition to existing investors the Development Bank of Wales and the UK Innovation and Science Fund.
Nemesis Bioscience closes funding round and begins preclinical programmes
Pioneering company poised to address global antimicrobial resistance crisis
Nemesis Bioscience appointS Dr Alastair Riddell as non-executive chairman
Nemesis Bioscience today announced the appointment of Dr Alastair Riddell as non-executive Chairman. The appointment, effective from 1st July, will bring Alastair’s considerable experience into the company as it continues to rapidly grow the business around its portfolio of Nemesis Symbiotics© which inactivate antibiotic resistance in pathogenic bacteria.
Nemesis Bioscience wins place at UK’s largest innovation show
Nemesis Bioscience has beaten tough competition from across the country to win a place to showcase its product at the UK’s largest innovation show in November. Nemesis was one of 100 companies to be selected to showcase its innovation to over 3,000 attendees at Innovate 2015 on November 9th and 10th at Old Billingsgate in London.
Nemesis Bioscience receives Innovate UK Smart funding award
Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has received a funding award from the UK’s innovation agency, Innovate UK. The Smart Award will be used to develop and protect a novel method for the delivery of polynucleotides, including therapeutics, into bacteria.
Nemesis Bioscience raises £300,000 in seed funding and opens development facility in Wales
Nemesis Bioscience Ltd has raised £300,000 in seed funding from Angel investors and from Finance Wales to extend the application of its proprietary biological therapeutics – Nemesis Symbiotics that inactivate antibiotic resistance.
Nemesis Bioscience wins King’s College Entrepreneurship Award
Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has been awarded an Entrepreneurship Award by King’s College, Cambridge. The King’s College judges, who include current members of the College as well as alumni Gerard Mizrahi, Hermann Hauser and Stuart Lyons, reached their decision after detailed presentations on the company’s business plan, technology and intellectual property.